Articles published by CSL Behring

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

July 04, 2024

From CSL Behring

Via GlobeNewswire

Tickers ASX CSLLY

Privacy Policy Terms of Service About

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.